Cardiothoracic Anesthesia Division
The Division of Cardiothoracic Anesthesia at the Mount Sinai Hospital has a long history of excellence in clinical care and continues to expand in the clinical and research domains. Our division provides anesthetic care to > 2000 adult and pediatric patients each year, in 7 cardiothoracic anesthetizing locations daily. All of our full-time divisional faculty is board certified in perioperative transesophageal echocardiography, and we perform approximately 1400 TEE exams each year.
Mount Sinai is a busy referral center for aortic reconstruction and mitral valve repair. Our cardiac surgical colleagues annually perform > 1000 cases requiring cardiopulmonary bypass, of which approximately 30% are myocardial revascularizations, 30% are complex and minimally invasive valve repairs, 15% are major operations on the thoracic aorta and 15% are congenital heart surgeries. The remainder include a variety of complex cases, including implantation of ventricular assist devices, surgical ventricular restorations and cardiac transplantation.
We also provide care to approximately 300-400 adult and pediatric patients undergoing diagnostic and interventional electrophysiological procedures and pediatric cardiac catheterizations, as well as 700-800 patients annually for a variety of thoracic procedures. There is a particular emphasis on minimally invasive procedures for all lung and esophageal surgery, and the vast majority of our thoracic cases are performed using video-assisted thoracoscopic techniques.
Research is flourishing in the Division of CT Anesthesia. The wide variety of disease states in the cardiac surgical population creates an environment in which almost every patient can participate in a clinical trial, if desired. Ongoing and recently completed projects have focused on: new monitoring techniques (including 3-D echocardiography, near infrared spectroscopy, non-invasive cardiac output monitoring and pulse contour analysis), medical informatics, techniques specific to pediatric and geriatric cardiac anesthesia, new pharmacologic agents (including new anti-hypertensive drugs, heart failure drugs, and anti-inflammatory strategies), coagulation and hemostasis, platelet function monitoring, transfusion algorithms, hemostatic substances for infusion and topical use, and evaluation of new anticoagulants.